-

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH)

NEW YORK--(BUSINESS WIRE)--iPredictTM late Stroke prediction model provides a fully automated prediction score for incident stroke and identifies the individuals who are at risk of stroke within 5-years. These results were presented at the international conference: Society for Brain Mapping and Therapeutics World Congress and show that the prediction model may help prevent stroke, saving millions of people from death or disability.

Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredictTM AI System, the stroke prediction results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes.

This prediction model offers an overall accuracy of 82.4% for identifying an individual at risk of having an incident stroke within 5-years.

iPredict achieved higher accuracy than existing stroke prediction models such as Framingham and Chads scores (iPredict-stroke accuracy 82.4% compared to Framingham score 64.9%, and the CHADS2VASC score achieved 63.8% accuracy respectively on the same dataset).

iPredict’s stroke model can be used to alert physicians of the need to take further preventive measures for these patients in the primary care setting.

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma which are CE certified and TGA/Australian health approved.

iHealthScreen company is open to partnerships for distribution and/or co-development of its products in various territories. For more information: https://www.iHealthScreen.org

Contacts

Alauddin Bhuiyan, Ph.D.
CEO, iHealthScreen Inc.
E: bhuiyan@ihealthscreen.org
T: +1 718 926 9000

More News From iHealthScreen

iHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy Screening

RICHMOND HILL, N.Y.--(BUSINESS WIRE)--iHealthScreen, Inc., a healthcare AI company developing Software as a Medical Device (SaMD) for retinal and cardiovascular disease screening and preventive healthcare, today announced FDA 510(k) clearance (K253704) for iPredict-DR™, its AI-powered software that automatically detects more than mild diabetic retinopathy (mtmDR) in adults with diabetes not previously diagnosed with the condition. Diabetic retinopathy is a leading cause of preventable blindness...

iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data

NEW YORK--(BUSINESS WIRE)--iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years. These results were peer-reviewed and accepted by the scientific review team and will be presented at the ESC Congress which will be held between 30th August and 2nd September 2024. The iPredict stroke and MI predic...

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

NEW YORK--(BUSINESS WIRE)--iPredictTM glaucoma detection model provides a fully automated detection report for glaucoma which can be implemented in the primary care settings for screening and detection of early-stage glaucoma. The full US patent was awarded by USPTO on March 26, 2024. Earlier the results were published in a scientific journal and the results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024. The early screening and detection of glaucoma c...
Back to Newsroom